Literature DB >> 15161658

Retinoblastoma protein is frequently absent or phosphorylated in anaplastic large-cell lymphoma.

George Z Rassidakis1, Raymond Lai, Marco Herling, Candy Cromwell, Annette Schmitt-Graeff, L Jeffrey Medeiros.   

Abstract

The possible role of retinoblastoma protein (Rb) in the pathogenesis of anaplastic large-cell lymphoma (ALCL) is unknown. We investigated Rb protein expression, both total (phosphorylated and underphosphorylated) and active (underphosphorylated), in four anaplastic lymphoma kinase (ALK)-positive ALCL cell lines (Karpas 299, JB-6, SU-DHL1, and SR-786) by Western blot analysis, and in 67 ALCL tumors (30 ALK-positive, 37 ALK-negative) using immunohistochemical methods. We also used fluorescence in situ hybridization and polymerase chain reaction methods to assess for loss of heterozygosity of the rb gene. The findings were correlated with apoptotic rate assessed by the terminal dUTP nick-end labeling assay. Immunoblots showed high total Rb levels in Karpas 299, SU-DHL1 and SR-786 and relatively lower levels in and JB-6. Underphosphorylated Rb was negative or expressed at low levels in all cell lines. In ALCL tumors, total Rb was detected in 44 (66%) and absent in 23 (34%). The mean apoptotic rate was 3.2% in Rb-negative tumors compared with 2.7%, 2.2%, and 1.2% in tumors with <10%, 10 to 50%, and >50% Rb-positive cells, respectively (P = 0.2, Kruskall-Wallis test). In a subset of 25 total Rb-positive tumors we assessed for underphosphorylated Rb, which was detected in 12 tumors. The detection of only total Rb in the remaining 13 tumors suggests that Rb was phosphorylated. Fluorescence in situ hybridization showed allelic loss of the rb gene in 10 (40%) of 25 tumors analyzed and was significantly associated with absence of Rb expression (P = 0.003). Similar results were obtained for loss of heterozygosity of the 13q14 locus. Five-year progression-free survival for patients with Rb-negative ALCL was 89.4% compared with 47.7% for patients with total Rb-positive ALCL (P = 0.006, log-rank test). Similar trends for progression-free survival held true for patients with ALK-positive and ALK-negative tumors analyzed separately. In conclusion, Rb is absent or phosphorylated in most ALCL cell lines and tumors and absence of Rb expression is associated with better clinical outcome in patients with ALCL.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15161658      PMCID: PMC1615788          DOI: 10.1016/S0002-9440(10)63782-0

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  44 in total

1.  A biological role for deletions in chromosomal band 13q14 in mantle cell and peripheral t-cell lymphomas?

Authors:  A Rosenwald; G Ott; A K Krumdiek; M H Dreyling; T Katzenberger; J Kalla; S Roth; M M Ott; H K Müller-Hermelink
Journal:  Genes Chromosomes Cancer       Date:  1999-11       Impact factor: 5.006

Review 2.  Corepressors and retinoblastoma protein function.

Authors:  J W Harbour; D C Dean
Journal:  Curr Top Microbiol Immunol       Date:  2001       Impact factor: 4.291

3.  A novel four-color PCR assay to assess T-cell receptor gamma gene rearrangements in lymphoproliferative lesions.

Authors:  F Vega; L J Medeiros; D Jones; L V Abruzzo; R Lai; J Manning; V Dunmire; R Luthra
Journal:  Am J Clin Pathol       Date:  2001-07       Impact factor: 2.493

4.  CD30-activation-mediated growth inhibition of anaplastic large-cell lymphoma cell lines: apoptosis or cell-cycle arrest?

Authors:  E Levi; W M Pfeifer; M E Kadin
Journal:  Blood       Date:  2001-09-01       Impact factor: 22.113

5.  Frequent disruption of the RB1 pathway in diffuse large B cell lymphoma: prognostic significance of E2F-1 and p16INK4A.

Authors:  M B Møller; P W Kania; Y Ino; A M Gerdes; O Nielsen; D N Louis; K Skjødt; N T Pedersen
Journal:  Leukemia       Date:  2000-05       Impact factor: 11.528

6.  Genomic aberrations and survival in chronic lymphocytic leukemia.

Authors:  H Döhner; S Stilgenbauer; A Benner; E Leupolt; A Kröber; L Bullinger; K Döhner; M Bentz; P Lichter
Journal:  N Engl J Med       Date:  2000-12-28       Impact factor: 91.245

7.  Differential expression of BCL-2 family proteins in ALK-positive and ALK-negative anaplastic large cell lymphoma of T/null-cell lineage.

Authors:  G Z Rassidakis; A H Sarris; M Herling; R J Ford; F Cabanillas; T J McDonnell; L J Medeiros
Journal:  Am J Pathol       Date:  2001-08       Impact factor: 4.307

8.  Phosphorylation-dependent migration of retinoblastoma protein into the nucleolus triggered by binding to nucleophosmin/B23.

Authors:  Masaharu Takemura; Fumiharu Ohoka; Marinela Perpelescu; Masanori Ogawa; Hidenobu Matsushita; Tomoyuki Takaba; Tetsu Akiyama; Hayato Umekawa; Yukio Furuichi; Peter R Cook; Shonen Yoshida
Journal:  Exp Cell Res       Date:  2002-06-10       Impact factor: 3.905

9.  Low expression of p27 protein combined with altered p53 and Rb/p16 expression status is associated with increased expression of cyclin A and cyclin B1 in diffuse large B-cell lymphomas.

Authors:  M Bai; J Vlachonikolis; N J Agnantis; E Tsanou; S Dimou; C Nicolaides; S Stefanaki; N Pavlidis; P Kanavaros; P Kanavarous
Journal:  Mod Pathol       Date:  2001-11       Impact factor: 7.842

10.  Proliferation-dependent expression and phosphorylation of pRB in B cell non-Hodgkin's lymphomas: dependence on RB1 copy number.

Authors:  E Galteland; L Smedshammer; Z Suo; P DeAngelis; T Stokke
Journal:  Leukemia       Date:  2002-08       Impact factor: 11.528

View more
  9 in total

Review 1.  Pathobiology of ALK+ anaplastic large-cell lymphoma.

Authors:  Hesham M Amin; Raymond Lai
Journal:  Blood       Date:  2007-05-22       Impact factor: 22.113

2.  Altered structure and deregulated expression of the tumor suppressor gene retinoblastoma (RB1) in human brain tumors.

Authors:  J Mathivanan; K Rohini; Mohan L Gope; B Anandh; Rajalakshmi Gope
Journal:  Mol Cell Biochem       Date:  2007-02-23       Impact factor: 3.396

3.  Highly aggressive behavior of malignant rhabdoid tumor: a special reference to SMARCB1/INI1 gene alterations using molecular genetic analysis including quantitative real-time PCR.

Authors:  Kenichi Kohashi; Yoshinao Oda; Hidetaka Yamamoto; Sadafumi Tamiya; Teiyu Izumi; Shigeru Ohta; Tomoaki Taguchi; Sachiyo Suita; Masazumi Tsuneyoshi
Journal:  J Cancer Res Clin Oncol       Date:  2007-05-08       Impact factor: 4.553

4.  Inhibition of Akt increases p27Kip1 levels and induces cell cycle arrest in anaplastic large cell lymphoma.

Authors:  George Z Rassidakis; Marianna Feretzaki; Coralyn Atwell; Ioannis Grammatikakis; Quan Lin; Raymond Lai; Francois-Xavier Claret; L Jeffrey Medeiros; Hesham M Amin
Journal:  Blood       Date:  2004-09-16       Impact factor: 22.113

5.  Reduced Retinoblastoma Protein Expression Is Associated with Decreased Patient Survival in Medullary Thyroid Cancer.

Authors:  Anisley Valenciaga; Elizabeth G Grubbs; Kyle Porter; Paul E Wakely; Michelle D Williams; Gilbert J Cote; Vasyl V Vasko; Motoyasu Saji; Matthew D Ringel
Journal:  Thyroid       Date:  2017-12       Impact factor: 6.568

Review 6.  MEG3: a novel long noncoding potentially tumour-suppressing RNA in meningiomas.

Authors:  Vladimir Balik; Josef Srovnal; Igor Sulla; Ondrej Kalita; Tatiana Foltanova; Miroslav Vaverka; Lumir Hrabalek; Marian Hajduch
Journal:  J Neurooncol       Date:  2013-01-11       Impact factor: 4.130

7.  Aberrant anaplastic lymphoma kinase activity induces a p53 and Rb-dependent senescence-like arrest in the absence of detectable p53 stabilization.

Authors:  Fiona Kate Elizabeth McDuff; Suzanne Dawn Turner
Journal:  PLoS One       Date:  2011-03-14       Impact factor: 3.240

8.  Pathobiology of anaplastic large cell lymphoma.

Authors:  Pier Paolo Piccaluga; Anna Gazzola; Claudia Mannu; Claudio Agostinelli; Francesco Bacci; Elena Sabattini; Carlo Sagramoso; Roberto Piva; Fernando Roncolato; Giorgio Inghirami; Stefano A Pileri
Journal:  Adv Hematol       Date:  2011-02-06

Review 9.  Treating hematological malignancies with drugs inhibiting ribosome biogenesis: when and why.

Authors:  Enrico Derenzini; Alessandra Rossi; Davide Treré
Journal:  J Hematol Oncol       Date:  2018-05-31       Impact factor: 17.388

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.